Halozyme Therapeutics, Inc.

Corporate Presentation

NASDAQ: HALO

February 2024

Halozyme

Forward Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2024 guidance and longer term financial outlook through 2028) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales, and revenue durability and diversification), EBITDA, Adjusted EBITDA, non-GAAP diluted earnings-per-share, expected growth rates of the Company's partnered products, potential share repurchases and the Company's plans to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery and administration of higher volumes of injectable medications through subcutaneous delivery and potential to decrease treatment burden, infusion related reactions and healthcare system costs and enable new treatment sites. Forward-looking statements regarding the Company's business may also include potential growth driven by our partners' development and commercialization efforts (including anticipated ENHANZE® indication and product approvals and launches and the timing related to these events), projections for future sales revenue and market share of our collaborators' products, potential new or expanded ENHANZE® collaborations, collaborative targets and indications for ENHANZE® products, the potential for co-formulation patents to extend royalty payment periods and maintain royalty rates, and the Company's plans to develop a high volume auto-injector (including statements related to potential future development, approval and patient treatment benefits of a high volume auto-injector). These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners and product sales), expenditures and costs, unexpected delays in the execution of the Company's planned platform expansion or share repurchases, unexpected results or delays in the growth of the Company's ENHANZE® business (including as a result of unexpected conversion rates) or other proprietary product revenues, obtaining new co-formulation or proprietary intellectual property, or in the development, regulatory review or commercialization of our partners' ENHANZE® products, unexpected delays in the Company's plans to develop and commercialize a high volume auto-injector, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Non-GAAP Financial Measures:
In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports Adjusted EBITDA, Adjusted EBITDA Margin and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company uses Non-GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. The Company does not provide reconciliations for forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, share based compensation expense and the effects of any discrete income tax items. Reconciliations between GAAP and non-GAAP financial measures are included in these materials.

Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners.

Company Overview

De-Risked and Proven Business Model Positioned for Durable Revenue Growth

High Probability of Technical Success	Royalty Revenue Inflection Point Now	Diversified Revenue	Durable Revenue	Broadly Compatible
10/10 success in positive IV to SC bioavailability non-inferiority Phase 3 data, following Phase 1 PK data	**7** Approved products as of 2023 **10** Approved products by 2025	ENHANZE® Auto-Injectors XYOSTED® Hylenex®	Innovation driven Co-formulation patents HVAI	Supports platform expansion

Our Vision



Subcutaneous delivery with ENHANZE® can result in…

1. **Decreased treatment burden**
   Treatment from hours to minutes[1]
2. **Lower infusion related reactions**[2]
3. **New treatment sites**
   Possible treatment in home, doctor's office, community hospital[3]
4. **Strong patient preference**
   81-89% of patients prefer SC versus IV[4]

[1] Phesgo® Prescribing Information and DARZALEX Faspro® Prescribing Information.
[2]Lancet Haematol. "Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomised, phase 3 trial"; 2020.
[3]VYVGART® Hytrulo Prescribing Information in Europe.
[4]Pivot X, Gligorov J, Müller V, et al. "Patients' Preference for SC vs. IV", Annals of Oncology, 2014; O'Shaughnessy, J et al. Eur J Cancer. 2021 Jul:152:223-232; Rummel M, et al. Ann Oncol. 2017;28:836--842; Wasserman RL et al . J Allergy Clin Immunol. 2012;130:951--957

Halozyme

Industry Leading Drug Delivery Platform Company

0–2 mLs

Small Volume Auto-Injector (SVAI) with Drug

1 approved proprietary drug/SVAI product

3 approved partner SVAI products

>40M devices supplied 2013-2023

2–10 mLs

High Volume Auto-Injector (HVAI) with Drug

First HVAI clinically demonstrated to deliver 10 mLs in <30secs

Offers patients option of at **home delivery** or **rapid delivery** in doctor's office

Goal to **expand upon** established ENHANZE collaborations & **add new** collaboration partners

>2 mLs

rHuPH20/ENHANZE®

ENHANZE®

- ✓ **7 approved** partnered products
- ✓ Approved in **100+ countries**
- ✓ **~800,000 patients** have received ENHANZE®- enabled treatments through January 2024

Proprietary Halozyme Products

$100M in XYOSTED® sales 2023

$25M in Hylenex® sales 2023

Subcutaneous Drug Delivery Can Decrease Healthcare System Costs and Improve Patient Experience

Current Challenges[1]

50%
of infusion centers surveyed needed major investment to keep up with patient treatment needs

- ✗ Limited number of infusion chairs
- ✗ Insufficient nurses to oversee treatments
- ✗ Pharmacies unable to keep up with demand

⌄⌄

- ✗ Lengthy wait times for treatment at the suite
- ✗ Sicker patients with delayed treatment

SC Delivery with ENHANZE®

97%
Reduced patient treatment time[2]

50%
Reduced healthcare practitioner time year 1 and 2[2]

Daratumumab SC versus IV[2]

71%
Lower patient time in clinic[3]

$4,171
Potential savings per treatment course[3]

Trastuzumab SC versus IV[3]

Halozyme

[1] The State of Cancer Centers 2022. Survey of 100 Centers. LeanTaaS.com
[2] Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab 2021 June 8:13:465-473 doi. 10.2147/CEOR.S302682. eCollection 2021
[3] Subcutaneous trastuzumab versus intravenous trastuzumab for the treatment of HER2-Positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. Eu. J Obstetrics and Gyn. 2018 Feb: 221:46-51

De-Risked and Proven Business Model Positioned for Durable Revenue and EBITDA Growth

Revenue[1]

2023 – 2024



2023 - 2028



Adjusted EBITDA[1]

2023 – 2024



2023 - 2028



Revenue Mix





[1] CAGR calculated from 2023 actual to 2028 midpoint

Leader in Disruptive Drug Delivery Technologies

ENHANZE® is Halozyme's Patent Protected, Commercially Validated rHuPH20 Enzyme

WHAT IT IS

ENHANZE® (rHuPH20) is an **enzyme that degrades hyaluronan** by cleaving the B-1,4 linkage between the N-acetyl glucosamine and glucuronic acid

WHAT IT DOES

ENHANZE® **reduces tissue backpressure creating** temporary space for SC fluid dispersion



HOW IT WORKS

ENHANZE® works rapidly, locally and transiently in SC space; HA is naturally restored within 1 – 2 days[1]

IMPACT

ENHANZE® **uniquely** facilitates rapid, large volume SC delivery

[1] Hompesch et. al. (2011) EASD National Meeting – 2011

7 Approved Products Projected to Grow to 10 in 2025

Wave 1 & 2

$20B[1]

Projected Sales of IV and SC by 2028

5 Globally-Approved Products

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units

PHESGO® PERTUZUMAB-TRASTUZUMAB

HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

RituxanHYCELA® [2] rituximab/hyaluronidase human subcutaneous injection | 1,400 mg/23,400 Units 1,600 mg/26,800 Units

Herceptin HYLECTA™ [3] trastuzumab and hyaluronidase-oysk INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units

Wave 3

$35B[1]

Projected Sales of IV and SC by 2028

Recently Launched

VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial

TECENTRIQ® SC [4] atezolizumab subcutaneous

2024-2025 Projected Launches

Atezolizumab SC: U.S.
Ocrelizumab SC
Nivolumab SC
Amivantamab SC

Halozyme Royalty Revenue $448M in 2023

$1B Royalty Revenue Potential for Halozyme in 2027

Halozyme

Licensees are responsible for development and commercialization
[1] Analysts' consensus from Evaluate Ltd January 2024
[2] Rituxan HYCELA® is marketed as MabThera® SC outside of the U.S
[3] Herceptin HYLECTA is marketed as Herceptin SC outside of the U.S.
[4] Approved in Great Britain and EU

Multiple Recent and Projected Product and Indication Launches Drive Near and Long-Term Royalty Revenue Growth



~$35B Projected Sales of Wave 3 Products (SC and IV) in 2028[1]

[1] Analysts' consensus from Evaluate Ltd January 2024

ENHANZE® Wave 4 Pipeline

7 Products in Development | **2** Products in Phase 3 | **1** Product in Phase 2

Current Program/Product	Study Indication	Phase 1	Phase 2	Phase 3	Filed
Wave 4[1]					
Nivolumab+Relatlimab (BMS)	Melanoma				
TAK-881 (Takeda)	Immune				
N6LS bnAb (ViiV)	HIV (treatment)				
Cabotegravir (ViiV)	HIV				
ARGX-117; Empasiprubart (argenx)	Multifocal motor neuropathy				
Undisclosed (Roche)	Undisclosed				
Undisclosed (Chugai)	Undisclosed				

[1] Wave 4 includes products with potential to launch by 2027, based on 4.5 -5 years from SC first in human, to launch

Developed and Clinically Tested FIRST High Volume Auto-Injector

What made this uniquely possible?

ENHANZE® + Halozyme Auto-Injector Technology and Know-How =

First HVAI Delivering 2-10 mLs in <30 seconds

Results

- ✓100% success
- ✓Well tolerated
- ✓High patient acceptance

Halozyme Expertise

- ✓ Full pharma and device development capabilities
- ✓ Multiple device/drug combination product approvals (U.S., EU)
- ✓ Emergency use and high-viscosity specialty

Operational and Commercial Achievements in 2023

Commercialization and Development Milestones

2023 Approvals

- VYVGART® Hytrulo (gMG) in U.S and EU
- Tecentriq® SC in Great Britain

Resulting in 7 commercial ENHANZE®-enabled products in up to 100 countries

Positive Phase 3 Data

- VYVGART® Hytrulo (CIDP)
- Atezolizumab SC
- Ocrelizumab SC
- Nivolumab SC

Pipeline Advancements

- Positive Phase 1 data amivantamab SC[1]
  - ✓ Supported dose selection
  - ✓ IRR 16% SC versus 67% IV
- N6LS Phase 2b study initiation
- New target Phase 1 start (undisclosed)

Innovation + Partnership Milestones

ENHANZE® + Halozyme Auto-Injector Technology and Know-How =

First HVAI delivering 10 mLs in <30secs

ACUMEN

- Non-exclusive agreement
- Upfront payment
- Milestones
- Single digit royalties

Halozyme

[1] Subcutaneous Amivantamab in Patients With Advanced Solid Malignancies: The PALOMA Study – Updated Safety and Confirmation of the Recommended Phase 2 Dose Presented at the American Society of Clinical Oncology Annual Meeting; June 2–6, 2023; Chicago, IL, USA

Innovation Supports Revenue Durability

Co-formulation Patents are Result of Licensee Collaborations

Co-formulation patents cover the licensed product, including:

- Product formulations
- Product dosing schedules and regimens
- Use of licensed product for treatment of disease/conditions

Patents are granted for innovations that are "non-obvious" or when there are “non-obvious” results including:

- Improved pharmacokinetic profile
- Improved therapeutic results
- Improved stability, improved drug potency or retention of potency
- Decoupling of pharmacokinetic and pharmacodynamic response
- Altered duration of release or effect
- Reduction in adverse events

Patents are valid 20 years from earliest filing date

- Patents take on average 3-5 years from filing to grant (U.S. & EU)

Products Granted Co-formulation Patents Due to Non-Obvious Innovation or Result

Reason for Patent Grant	HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]	Herceptin HYLECTA™ trastuzumab and hyaluronidase-oysk INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units	RituxanHYCELA® rituximab/hyaluronidase human subcutaneous injection | 1,400 mg/23,400 Units 1,600 mg/26,800 Units	DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units	PHESGO® PERTUZUMAB-TRASTUZUMAB
Non-obvious combination, dosage and/or method of administration	✓		✓		
Unexpected stability of co-formulation		✓			✓
Improved response rate with SC versus IV				✓	
Reduced infusion related reactions				✓	

Halozyme

Licensed Partner Products: Anticipated Royalty Term/Rate for Waves 1, 2, 3

Product Name	Co-formulation Patent Status & Anticipated Impact
Herceptin SC	Granted (royalty to expiry 07/2030)
Mabthera SC	Granted (royalty to expiry 09/2030)
Phesgo®	Granted (royalty to expiry 07/2030)
DARZALEX SC (OUS)	Granted; royalty 12 years post first commercial sale
DARZALEX Faspro® (U.S.)	Granted; royalty 12 years post first commercial sale
HyQvia 10%	Granted, royalty to expiry 09/2030
Tecentriq® SC[1]	Pending, if patent granted, royalties to 12/2040
Ocrelizumab SC[2]	10-year term; no royalty reduction through 9/2030 if pending patent granted
VYVGART® Hytrulo	Pending, if patent granted, royalties to early 2040s

Amivantamab SC and Nivolumab SC not included, because consent to display information for those products not obtained from the licensees
Except for DARZALEX® SC and DARZALEX Faspro®, does not account for non-public (un-published) pending co-form applications
Royalty terms are estimated based on earliest co-form filing date
[1] Tecentriq® SC is approved in Great Britain and EU
[2] Ocrelizumab SC not yet approved or launched

Royalty Revenue Guidance Driven by 10 ENHANZE Partnered Products, 7 Approved and 3 Additional Projected Product Approvals by 2025



Clear Path to Delivering Sustainable Growth

Looking Ahead: 2024 and Beyond Total and Royalty Revenue

Total Revenue ($M)



Total Royalties ($M)



- Assumes step down outside U.S. in DARZALEX® SC royalties March 2024
- Assumes step down in U.S. DARZALEX® SC royalties September 2027
- Only includes Wave 1, 2 and 3

[1]Growth rates calculated from midpoint to midpoint

Looking Ahead: 2024 and Beyond EBITDA and EPS

Adjusted EBITDA ($M)



Non-GAAP Diluted EPS ($ per share)



[1]Growth rates calculated from midpoint to midpoint

[2]2025 YoY adjusted EBITDA growth rate decelerates as Collaboration Revenue projected to remain stable YoY

[3]2025 YoY non-GAAP Diluted EPS growth rate decelerates as Collaboration Revenue projected to remain stable YoY, interest income rates projected to decline, and new share issuance due to stock-based compensation

Halozyme

Looking Ahead: 2024 and Beyond

$M, except EPS (unaudited)	2023 Actual	2024 Guidance	2025	2026	2027	2028	2023-2028 CAGR[7]
Royalties[1]	447.9	500 – 525	595 – 620	750 – 790	975 – 1,025	1,000 – 1,050	18%
Product Sales[2]	300.9	285 – 300	315 – 335	385 – 415	410 – 455	435 – 480	9%
Collaboration Revenue[3]	80.5	130 – 160	130 – 160	130 – 160	130 – 160	130 – 160	12%
Total Revenue	829.3	915 – 985	1,040 – 1,115	1,265 – 1,365	1,515 – 1,640	1,565 – 1,690	14%
Adjusted EBITDA[4]	426.2	535 – 585	655 – 705	855 – 935	1,070 – 1,195	1,125 – 1,250	23%
Adjusted EBITDA Margin[5]	51%	58% – 59%	63% – 63%	68% – 68%	71% – 73%	72% – 74%	7%
Non-GAAP Diluted EPS[6]	2.77	3.55 – 3.90	4.10 – 4.50	5.30 – 5.80	6.70 – 7.30	6.90 – 7.50	21%

[1] Royalty projections based on approved ENHANZE® products and assumes global approval and launches of VYVGART® Hyrulo CIDP, Atezolizumab SC in US, Ocrelizumab SC, Nivolumab SC and Amivatamab SC and all approved Auto-Injector products. Assumes impact of pending or issued co-formulation patents. Does not include the impact of Halozyme pending patents. Innovator revenues based on Evaluate Ltd analyst-based estimates as of December 2023 when available otherwise based on select analyst estimates. Conversion rates based on Halozyme internal projections. Projected royalty revenue is not risk-adjusted. Royalty rate on average mid-single digit range across all products.

[2] Product sales projections based on XYOSTED® and Hylenex® commercial products and sales of ENHANZE® API and auto-injector devices to collaboration partners

[3] Collaboration revenue includes development, regulatory, and commercial milestones for certain ENHANZE® and SVAI development programs currently advancing and projected new deals

[4] Adjusted EBITDA projections represent earnings before interest income/expense, tax, and depreciation and amortization with adjustments for one-time, non-recurring items

[5] Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by Total Revenue

[6] Non-GAAP Diluted EPS excludes impact of potential future share repurchases

[7] 2023-2028 CAGR % is calculated from 2023 actual to 2028 midpoint

All projections exclude the impact of potential future M&A

Halozyme

2024 Financial Guidance Highlights

$M, except EPS	2023 Results	2024 Guidance[1]	
Total Revenue	$829	**$915 - $985**	• 10-19% YOY growth • Total collaboration revenue expected to increase compared to 2023 inclusive of new deals • Product sales growth from XYOSTED®; projecting API sales decline due to price reductions resulting from yield improvements • Milestones and API sales to be substantially weighted in the second half of the year
Royalty Revenue	$448	**$500 - $525**	• 12-17% YOY growth • Continued DARZALEX® SC and Phesgo® Wave 2 growth • Wave 3 uptake driven by VYVGART® Hytrulo and Tecentriq® SC • Sequential growth to flatten in the first and second quarter, growth sequentially thereafter
Adjusted EBITDA	$426	**$535 - $585**	• 26-37% YOY growth • YoY growth driven by gross margin expansion from revenue mix • Adjusted EBITDA margin increasing from 51% in 2023 to 58-59% in 2024
Non-GAAP Diluted EPS	$2.77	**$3.55 - $3.90**	• 28-41% YOY growth • YoY growth driven by gross margin expansion from revenue mix and full year impact of 2023 share repurchase activity

Halozyme

[1] Growth rates calculated from 2023 actuals to low end of 2024 range and midpoint of 2024 range

Capital Allocation Priorities

Invest to Maximize Revenue Growth and Durability

- ✓ ENHANZE®
- ✓ HVAI and auto-injector innovation

Return Capital to Shareholders

- ✓ Initiated $250M ASR in 4Q23 to be completed in 2024, for a total of $400M deployed in 2023
- ✓ Announced Board approval for new $750M share buyback program in February 2024
- ✓ Returned $1.3B (inclusive of ongoing $250M ASR) to shareholders in share buybacks over the past 5 years

Identify Opportunities for External Growth

- ✓ Continue to evaluate opportunities to accelerate and extend revenue

Committed to Balanced Capital Allocation With a Focus on Driving Growth and Value for Shareholders

Our Vision



Subcutaneous delivery with ENHANZE® can result in…

1. **Decreased treatment burden**
   Treatment from hours to minutes[1]
2. **Lower infusion related reactions**[2]
3. **New treatment sites**
   Possible treatment in home, doctor's office, community hospital[3]
4. **Strong patient preference**
   81-89% of patients prefer SC versus IV[4]

[1] Phesgo® Prescribing Information and DARZALEX Faspro® Prescribing Information.
[2]Lancet Haematol. "Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicenter, open-label, non-inferiority, randomised, phase 3 trial"; 2020.
[3]VYVGART® Hytrulo Prescribing Information in Europe.
[4]Pivot X, Gligorov J, Müller V, et al. "Patients' Preference for SC vs. IV", Annals of Oncology, 2014; O'Shaughnessy, J et al. Eur J Cancer. 2021 Jul:152:223-232; Rummel M, et al. Ann Oncol. 2017;28:836--842; Wasserman RL et al . J Allergy Clin Immunol. 2012;130:951--957

Halozyme

GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

$ in Thousands	Twelve Months Ended December 31, 2023	2022
GAAP Net Income	**$ 281,594**	**$ 202,129**
Adjustments		
Investment and other income	(16,317)	(1,046)
Interest expense	18,762	16,947
Income tax expense	66,735	46,789
Depreciation and amortization	84,856	49,641
EBITDA	**435,630**	**314,460**
Adjustments		
Gain on changes in fair value of contingent liability[1]	(13,200)	—
Inventory write-off[2]	3,509	—
Transaction costs for business combinations[3]	278	21,934
Severance and share-based compensation acceleration expense[4]	—	22,552
Adjusted EBITDA	**$ 426,217**	**$ 358,946**

1) Amount relates to fair value gain on contingent liability due to the due to the termination of the TLANDO license agreement in September 2023 (“TLANDO Termination”).
2) Amount relates to inventory write-off due to TLANDO Termination and amortization of the inventory step-up associated with purchase accounting for the prior year Antares acquisition.
3) Amounts represent incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year Antares acquisition.
4) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.

GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS

$ in Thousands	Twelve Months Ended December 31, 2023	2022
GAAP Net Income	**$ 281,594**	**$ 202,129**
Adjustments:		
Inducement expense related to convertible notes	—	2,712
Share-based compensation	36,620	24,397
Amortization of debt discount	7,304	7,839
Amortization of intangible assets	71,266	43,148
Transaction costs for business combinations[1]	278	21,934
Severance and share-based compensation acceleration expense[2]	—	22,552
Amortization of inventory step-up at fair value[3]	2,560	8,931
Realized loss from marketable securities[4]	—	1,727
Prior year income tax benefit[)	(5,375)	—
TLANDO Related Adjustments:		
Gain on changes in fair value of contingent liability[5]	(13,200)	—
Inventory write-off[5]	3,509	—
Impairment charge of TLANDO product rights intangible assets[5]	2,507	—
Income tax effect of above adjustments[6]	(15,753)	(24,025)
Non-GAAP Net Income	**$ 371,310**	**$ 311,344**
GAAP Diluted EPS	**$ 2.10**	**$ 1.44**
Adjustments		
Inducement expense related to convertible notes	—	0.02
Share-based compensation	0.27	0.17
Amortization of debt discount	0.05	0.06
Amortization of intangible assets	0.53	0.31
Transaction costs for business combinations[1]	—	0.16
Severance and share-based compensation acceleration expense[2]	—	0.16
Amortization of inventory step-up at fair value[3]	0.02	0.06
Realized loss from marketable securities[4]	—	0.01
Prior income tax benefit adjustments	(0.04)	—
TLANDO Related Adjustments		
Gain on changes in fair value of contingent liability[5]	(0.10)	—
Inventory write-off[5]	0.03	—
Impairment charge of TLANDO product rights intangible assets[5]	0.02	—
Income tax effect of above adjustments[6]	(0.12)	(0.17)
Non-GAAP Diluted EPS	**$ 2.77**	**$ 2.21**
GAAP & Non-GAAP Diluted Shares	**134,197**	**140,608**

1) Amount represents incremental costs including legal fees, accounting fees and advisory fees incurred for the prior year Antares acquisition.
2) Amount represents severance cost and acceleration of unvested equity awards as part of the Antares merger agreement.
3) Amounts relate to amortization of the inventory step-up associated with purchase accounting for the Antares acquisition.
4) Amount represents a realized loss from the sale of our marketable securities to finance the prior year acquisition of Antares.
5) Amounts relate to a fair value gain on contingent liability, inventory write-off and impairment of TLANDO product rights intangible assets due to the TLANDO Termination.
6) Adjustments relate to taxes for the reconciling items, as well as excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items.

Dollar amounts, as presented, are rounded. Consequently, totals may not add up.

Halozyme